Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics
Could opioids be silently undermining cancer immunotherapy?
This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials.
From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translational science, and biotech entrepreneurship, you won’t want to miss this episode.
Justin Chickles
CEO
Justin Chickles is the CEO and co-founder of Glycyx Therapeutics, a clinical-stage biotech company tackling a hidden cause of immunotherapy failure in cancer patients: opioids. With a background leading ventures across therapeutics, diagnostics, and digital health, Justin has spent the last four years advancing axelopran, a first-in-class therapy designed to reverse opioid-induced immunodeficiency. Under his leadership, Glycyx has progressed from scientific insight to a Phase 2 human trial launching this fall. Prior to Glycyx, he held executive roles at Johnson & Johnson and multiple venture-backed startups.